Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration

CHICAGO--(BUSINESS WIRE)--Dec 22, 2022--

Related Keywords

New Jersey ,United States ,Iris Shaffer ,Infliximab Biosimilar ,Public Health Service Act ,Subcutaneous Administration ,European Union ,Drug Administration ,Biologics License Application ,Hyoung Ki Kim ,Vice Chairman ,Jaeik Shim ,Chief Operating Officer ,Celltrion United ,Good Manufacturing Practice ,Celltrion Healthcare ,Celltrion United States ,Patients With Moderately ,Severely Active Ulcerative Colitis ,Severely Active Crohn ,Novel Formulation ,Part Two ,Controlled Trial ,Business Wire ,Illinois ,